Scientists at the Fred Hutchinson Cancer Center in Seattle and other research centers have successfully tested an HIV vaccine with nanoparticles. The participants had a sustained T-cell immune response. Clinical trial results published in Science Translational Medicine (STM).

The antigen used in the preparation was developed by IAVI (International AIDS Vaccine Initiative) and the Scripps Institute. Previous work has shown that it stimulates VRC01 class B cells, resulting in the neutralization of approximately 90 percent of HIV strains.

Now the authors have demonstrated in a phase 1 randomized, double-blind, placebo-controlled trial that the vaccine produces a strong CD4 T cell response. Also increased the number of T-follicular helper cells GC lymph nodes. In addition, several broad profile immunogenic epitopes have been identified that may be useful for the development of boosters and other vaccines.

Related materials:Nothing to breathe. How oxygen affects the aggressiveness of cancerous tumors

The experiment involved two groups, each of which had 18 people who received the drug, as well as six people with a placebo. The participants were given two doses of the vaccine or a placebo, eight weeks apart.

In December 2021, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced that it had successfully tested a human immunodeficiency virus (HIV) vaccine in animals.